Search

Aim: Bioresorbable vascular scaffolds (BVS) over the years have emerged as a new treatment option in coronary revascularization. There is a limited data on the use of these novel devices in patients with acute myocardial infarction (AMI). The purpose of this study was to evaluate the safety feasibility and efficacy of BVS implantation in patients with AMI., Methods and Results: 61 patients diagnosed for AMI underwent Absorb BVS device implantation. The mean age of the patients were 56.6 years with 86.89 % males. 34 patients has history of hypertension (HTN, 55.7%), 3 patients had history of myocardial infarction (MI,4.91 % ), 7 patients were diagnosed with unstable angina ( UA,11%), 34 patients had anterior wall ST elevation myocardial infarction ( AWSTEMI,55.73%),13 with ST segment elevation myocardial infarction ( STEMI,21.31%), with Killips class 2 (39.34%), 6 patients had Non ST segment Elevation Myocardial Infarction (NSTEMI, 9.83%). Procedural success was achieved in 93% patients with thrombolysis in myocardial infarction flow (TIMI) 3. During the follow up period of minimum 44±16 months no peri-procedural MACE were reported. Incidence of TLF (22.95%),definite probable ScT (11.47%) and TLR was 8 %. Average duration of DAPT was 17.57 months and 8 days. Cardiac death occurred in 4 patients (6.5%) after discharge from the hospital., Conclusions: The study results suggest that BVS implantation is feasible and safe in AMI. Specific device implantation technique is critical step towards success of BVS devices., (© Journal of the Association of Physicians of India 2011.)

Aims: Although the proof of concept of the bioresorbable vascular scaffold (BRS) is well documented, device-related adverse outcomes with first-generation BRS indicate longer-term surveillance. The current study provides insights into the safety and performance of the MeRes100, a novel second-generation sirolimus-eluting BRS, beyond one-year up to three-year follow-up (FU)., Methods and Results: A total of 108 enrolled patients with de novo coronary artery lesions who underwent implantation of MeRes100 as part of the first-in-human MeRes-1 trial were followed up clinically beyond one year at two and three years and with multiple modality imaging at six months and two years. At three-year FU, the cumulative major adverse cardiac events rate was 1.87%, in the form of two ischaemia-driven target lesion revascularisations. No scaffold thrombosis was reported. Between six months and two years at quantitative coronary angiography, in-segment late lumen loss (LLL) (0.15±0.22 mm vs. 0.23±0.32 mm; p=0.18) and in-scaffold LLL (0.13±0.22 mm vs. 0.24±0.34 mm; p=0.10) changed insignificantly. IVUS subset analysis revealed a non-significant reduction in mean lumen area (6.17±1.28 mm2 vs. 5.47±1.50 mm2; p=0.21) and minimum lumen area (5.14±1.19 mm2 vs. 4.05±1.42 mm2; p=0.10) at two years compared to post-procedural measurements. OCT subset analysis demonstrated 99.24±2.27% neointimal strut coverage., Conclusions: The extended outcomes of the MeRes-1 trial demonstrated sustained efficacy and safety of the MeRes100 BRS with maintained lumen patency up to two years by multimodality imaging and no very late scaffold thrombosis up to three-year clinical FU.The MeRes-1 trial is registered at the Clinical Trials Registry-India. CTRI Number: CTRI/2015/04/005706.

Objective: The e-BioMatrix is a post marketing multicenter registry with an objective to evaluate the 2 year clinical safety and efficacy outcomes in patients treated with BioMatrix™ - Biolimus A9™ (BA9™) drug eluting stents (DES)., Background: Drug-eluting stents still have late-stage disadvantages that might be attributable to the permanent polymer. BioMatrix a new generation DES containing anti-proliferative drug Biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia., Methods: This interim analysis consists of a total of 1189 patients with 1418 lesions treated with BioMatrix stent who entered this multicenter registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, and 12 months with an extended follow-up of 2 years. Recommended antiplatelet regimen included clopidogrel and aspirin for 12 months., Results: The mean age was 57.6 ± 10.9 years, 81.8% were males, comorbidity index was 1.20 ± 1.33, 68% presented with acute coronary syndrome, 49% had hypertension and 40.8% had diabetes mellitus. One-year clinical follow-up was completed in 987 patients at the time of interim analysis. The incidence of MACE is 0.45 for 1544 person-year follow-up. There were only 03 cases of ST (01 late ST) reported during this time., Conclusion: This registry demonstrates excellent one-year clinical safety and efficacy of BioMatrix stents. The 1-year result shows that BioMatrix stent may be a suitable alternative as compared to contemporary DESs which are currently available in the market for simple as well complex disease., (Copyright © 2013 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)